In the context of ovarian cancer, Zhang [23] demonstrated that C5aR1 blockade reshapes the immunosuppressive tumor microenvironment in high-grade serous ovarian cancer, suggesting that targeting complement signaling could enhance the effectiveness of immune checkpoint blockade therapy. The gene discussed is C5AR1; the disease is neoplasm.